Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in
hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The
primary objective of this study is to demonstrate, that a combination therapy of
hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in
participants with moderate COVID-19.
Phase:
Phase 4
Details
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Collaborators:
Hospital Schwabing Munich, Germany Missioklinik, Wuerzburg, Germany St. Georg Hospital Leipzig, Germany Universitätsklinikum Hamburg-Eppendorf University Hospital, Frankfurt